About

About DeepLife DeepLife is a biotech company transforming drug development through artificial intelligence and digital twin technology. Our platform leverages an AI-driven engine that maps cell-type-specific networks, utilizing over 100 million harmonized single-cell omics data points to identify targets and analyze regulatory networks with unprecedented precision. Our modular platform rests on three pillars: a comprehensive data foundation, sophisticated target identification algorithms, and advanced drug repurposing capabilities. We deploy this technology both for our internal drug repurposing pipeline and for partner collaborations focusing on target identification, derisking assets, indication expansion, and disease relevance assessment. This approach dramatically accelerates development by finding new applications for compounds with established safety profiles. Supported by $10M Series A funding and strategic collaborations with partners like Beiersdorf on skin diseases and aging, DeepLife simulates drug effects at the cellular level, opening doors to novel therapies. Our AI-driven simulations and multi-omics analytics enable pharmaceutical partners to develop precision treatments that are more targeted, faster, and cost-effective in addressing complex medical challenges.